Intralesional Tetracycline Injection in the Treatment of Chalazia (TET)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01763437 |
Recruitment Status :
Withdrawn
(Investigator left the institution)
First Posted : January 8, 2013
Last Update Posted : January 12, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chalazia Chalazion | Drug: Tetracycline | Early Phase 1 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Intralesional Tetracycline Injection in the Treatment of Chalazia |
Study Start Date : | March 2014 |
Estimated Primary Completion Date : | March 2015 |
Estimated Study Completion Date : | March 2015 |

Arm | Intervention/treatment |
---|---|
No Intervention: Observation
30 patients will be randomized to observation alone. These patients will return 4 weeks (+/- 2 weeks) after their initial visit for lesion measurement and photographs.
|
|
Experimental: Tetracycline
30 patients will be randomized to treatment with an intralesional injection of 0.05 mL of 2% tetracycline solution. These subjects will return 4 weeks (+/- 2 weeks) after treatment for lesion measurement and photographs.
|
Drug: Tetracycline
Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution. |
- Lesion size [ Time Frame: 4 weeks ]The size of the lesion will be measured as well as photographed. Photographs will be reviewed by a masked chalazion photograph reviewer.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age older than 18 years
- Not pregnant
- Chalazia of greater than 1 week duration
- Not allergic to tetracycline or its derivatives
- Not currently taking tetracycline or not taking them in the past 3 months
Exclusion Criteria:
- Age less than 18 years old
- Pregnancy
- Chalazia of less than 1 week duration
- Allergies to tetracycline or its derivatives
- Currently taking tetracyclines or have taken them in the past 3 months

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01763437
United States, Ohio | |
Cleveland Clinic Cole Eye Institute | |
Cleveland, Ohio, United States, 44145 |
Principal Investigator: | Julian D Perry, M.D. | Cleveland Clinic Cole Eye Institute |
Publications of Results:
Other Publications:
Responsible Party: | The Cleveland Clinic |
ClinicalTrials.gov Identifier: | NCT01763437 History of Changes |
Other Study ID Numbers: |
TET2013 |
First Posted: | January 8, 2013 Key Record Dates |
Last Update Posted: | January 12, 2017 |
Last Verified: | January 2017 |
Chalazia Chalazion Meibomian gland dysfunction Rosacea Ocular rosacea |
Chalazion Cysts Neoplasms Eyelid Diseases Eye Diseases Tetracycline |
Anti-Bacterial Agents Anti-Infective Agents Protein Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |